UCB - Big in Japan
Last night, UCB announced approval of both RYSTIGGO® and zilucoplan ‘ZILBRYSQ®' for the treatment of generalysed myasthenia gravis (gMG) in Japan. ZILBRYSQ® is the 1st approved self-administered innovative gMG solution, allowing for administration at home thereby offering additional patient comfort and differentiating it from the competition, including ARGX's VYVGART® (Hytrulo).This 1st approval for zilucoplan adds a 2nd option to UCB's gMG treatment arsenal, following the June US approval of rozanolixizumab. We foresee these drugs to coexist (rather than cannabilize) since ZILBRYSQ® is intended to be used as a long-term maintenance treatment while RYSTIGGO® is positioned as an add-on treatment duringUCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.